Companies and People News for September 2021

Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly Touchlight extends funding round to US$125M as demand for its dbDNA™ grows rapidly

Demand for Touchlight’s synthetic DNA vector has grown rapidly since last year.dbDNA™ is driving biomedical innovations such as DNA and mRNA vaccines, synthetic DNA-based neutralising antibody therapies, and more.Touchlight’s synthetic DNA vector is revolutionising genetic medicine manufacture by offering a superior alternative to traditional plasmid DNA.
16 September, 2021